Univ. of Wisconsin

Platinum agents are the usual first-line treatment for advanced NSCLC

Published in Hospital and Nursing Home Week, April 15th, 2004

First-line treatment of advanced non-small cell lung cancer with platinum-based agents is the standard of care, with docetaxel being the standard agent for second-line treatment, researchers report.

According to recent research published in the journal Hematology - Oncology Clinics of North America, "Lung cancer is an aggressive disease with poor prognosis after it has advanced. Over the past several years, there has been slow but steady progress in treatment options.

"Chemotherapy results in a modest improvement in survival, improved quality of life, and decreased pulmonary symptoms. For first-line treatment, platinum-based regimens have...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week

Source: Hospital and Nursing Home Week (2004-04-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry